Positive clinical trial results often lead to an increase in a biotech company's stock price, as it indicates progress in the company's pipeline and increases the potential for future revenue. Therefore, the positive results from Lineage Cell Therapeutics' RG6501 (OpRegen) trial could potentially boost the company's stock in the short term.